MNCs Need China-Oriented Oncology Strategy Mixed With Pricing Know-how
This article was originally published in The Pink Sheet Daily
Global players need to consider offering assistance in China, where most patients pay nearly 50 percent of their medical expenses out of pocket, and most simply cannot afford brand name innovative oncology drugs.
You may also be interested in...
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies
Already a big player in the world's largest pharmemerging market, China, Bayer is plunging deeper and reallocating more resources in capital investment and manpower to emerging markets
Building A New Model For Developing New Therapies: An Interview With AstraZeneca's Strategic Alliance Asia Director Richard Wang
Although AstraZeneca is paring down its pipeline by halting discovery efforts in 10 specific diseases, which account for 25 percent of the total diseases that earlier drove research by AstraZeneca ("The Pink Sheet" Daily, March 2, 2010), it won't stop R&D expansion plans in China. As big pharmaceutical firms compete to find the next generation of innovative drugs, translational science may help companies to find the right drug for the right patient and bring these medicines to market faster. During the recent Asia Pharma R&D Leaders conference in Shanghai, Richard Wang, AstraZeneca's Director of Strategic Alliances - Asia, sat down with PharmAsia News' Shanghai Bureau to discuss the strategy of AstraZeneca's Innovation Center China and how translational science is helping the company develop new compounds.